Pricing · Federal deal
Brand GLP-1s fall to about $350 on TrumpRx
Under a deal announced by the Trump administration with Eli Lilly and Novo Nordisk, brand GLP-1s sold through the federal TrumpRx platform fall to roughly $350 a month. Zepbound moves from a list price above $1,080 to an average of about $346. That is the single largest change to GLP-1 economics since compounding began, and it compresses the gap that the entire compounded market was built on.
What the deal does
It applies most-favored-nation pricing to GLP-1s through a federal direct-purchase channel. Ozempic, Wegovy and Zepbound all land near $350 a month cash. Reporting also indicates that the initial dose of any future FDA-approved oral GLP-1 will be priced at $150 a month from either manufacturer on the platform.
What it does to compounded pricing
Compounded programs have always sold one proposition: the same molecule, far cheaper than the brand, with the regulatory review removed. That pitch depends entirely on the size of the gap.
In our dataset the cheapest compounded tirzepatide is $169 a month all-in and the cheapest compounded semaglutide is $129. Against a brand price above $1,000, those are transformative numbers. Against roughly $350 for an FDA-approved product, they are a saving of a couple of hundred dollars a month — real money, but now competing against a medicine that has been through review, is manufactured to approved-drug standards, and cannot have its supply lane closed by a rulemaking.
The programs most exposed are the ones in the upper half of our field. Anything charging more than about $350 a month for a compounded product is now more expensive than the approved alternative through this channel, and has nothing left to argue except availability.
Why these figures are not in our rankings
They are reported, not captured. This site's rule is that a price enters the dataset when our desk captures it first-party at the point of sale, with a URL and a date. Until we do that for TrumpRx, the brand benchmarks in our rankings remain the channels we have captured — LillyDirect (Zepbound) at $449 a month and NovoCare for semaglutide.
That is deliberately conservative, and it means our brand comparisons currently overstate what an insured or TrumpRx-eligible buyer would pay. Read them with that in mind, and check the federal channel before assuming compounded is cheaper for you.
What to do with this
Before comparing any cash price on this site, check what an approved product costs you through TrumpRx, through Medicare if you are eligible, and through your insurer. Any of the three can now beat the compounded field. The cash-price comparisons here are for people none of those routes serve — which is still a great many people, but fewer than it was six months ago.
Verified . Regulatory positions, prices and trial results move — check the primary source before relying on a date. Compounded tirzepatide and semaglutide are not FDA-approved products.
Questions
How much do GLP-1s cost on TrumpRx?
Roughly $350 a month for Ozempic, Wegovy and Zepbound. Zepbound moves from a list price above $1,080 to an average of about $346. Reporting indicates the initial dose of future FDA-approved oral GLP-1s will be $150 a month on the platform.
Is compounded tirzepatide still cheaper than the brand?
At the bottom of the field, yes — the cheapest compounded tirzepatide in our dataset is $169 a month all-in against roughly $350 through TrumpRx. Above about $350, a compounded program is now more expensive than an FDA-approved product through that channel.
Why is TrumpRx not in your price rankings?
Because we have not captured it first-party. This site only ranks figures our desk has captured at the point of sale with a URL and a date. Reported prices are described in articles like this one but do not enter the dataset.